Print

HemoCue Defends Its Hemoglobin Patent Against EKF diagnostic GmbH And Stanbio Laboratory  
12/12/2005 12:23:10 PM

LAKE FOREST, Calif., Dec. 12 /PRNewswire/ -- HemoCue AB, a privately held Swedish manufacturer of medical diagnostic systems and HemoCue, Inc. announce that, as part of their effort to enforce their hemoglobin cuvette patent against German manufacturer EKF diagnostic GmbH and its U.S. distributor, Stanbio Laboratory, L.P., the patent is currently being reexamined by the U.S. Patent Office. The HemoCue companies are confident of a favorable outcome for their reexamination and enforcement efforts.

HemoCue is a leader in the development, manufacturing and marketing of advanced medical testing systems that bring lab-quality results to the point-of-care. Its leading products include hemoglobin, glucose, and urine albumin point-of-care testing systems. These products find a wide use in modern health care such as the ER, for assessment of blood loss and in primary care for anemia screening, diagnosis of diabetes and for the early detection of renal and cardiovascular disease. For additional product information, please call +1 800-323-1674 or visit http://www.hemocue.com.

HemoCue AB

CONTACT: Clas Runnberg, Head of Corporate Affairs, +46 431 45 82 70,clas.runnberg@hemocue.se, or Don DuBois, General Manager, +1 949 859 3070,don@hemocue.com, both of HemoCue AB


//-->